Safety and immunogenicity of the 23-valent pneumococcal polysaccharide vaccine at 12 months of age, following one, two, or three doses of the 7-valent pneumococcal conjugate vaccine in infancy.
FM Russell;
PV Licciardi;
A Balloch;
V Biaukula;
L Tikoduadua;
JR Carapetis;
J Nelson;
AWJ Jenney;
L Waqatakirewa;
S Colquhoun;
+3 more...
YB Cheung;
MLK Tang;
EK Mulholland 
;
(2010)
Safety and immunogenicity of the 23-valent pneumococcal polysaccharide vaccine at 12 months of age, following one, two, or three doses of the 7-valent pneumococcal conjugate vaccine in infancy.
Vaccine, 28 (18).
pp. 3086-3094.
ISSN 0264-410X
DOI: 10.1016/j.vaccine.2010.02.065
;
(2010)
Safety and immunogenicity of the 23-valent pneumococcal polysaccharide vaccine at 12 months of age, following one, two, or three doses of the 7-valent pneumococcal conjugate vaccine in infancy.
Vaccine, 28 (18).
pp. 3086-3094.
ISSN 0264-410X
DOI: 10.1016/j.vaccine.2010.02.065
Fijian infants aged 6 weeks were stratified by ethnicity and randomized to receive 0, 1, 2, or 3 PCV-7 doses with or without the 23-valent pneumococcal polysaccharide vaccine (PPV-23) at 12 months. Strong booster effects for all 7 PCV-7 serotypes were elicited, and for 4/7 serotypes these responses were highest in the single PCV-7 group. There were fourfold rises in GMC for all non-PCV-7 serotypes. By 17 months the PPV-23 group still had significantly higher GMC (each p<0.001) for all serotypes. The PPV-23 was well tolerated and induced excellent responses for all serotypes which were greatest in the single PCV-7 group.
Full text not available from this repository.
Downloads